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1.1 Cardiovascular diseases and comorbidities 
As both mortality and health care expenditures attributable to cardiovascular 
diseases and comorbidities far exceed the corresponding measures related to every other 
causes in the developed countries [1, 2], it is of paramount importance to facilitate the 
understanding of the underlying pathomechanism and the development of effective 
therapeutic approaches for these conditions. Particularly, the overwhelming majority of 
cardiovascular mortality is due to ischemic heart disease [3]. 
1.1.1 Ischemic heart disease and myocardial infarction 
The pathophysiology of ischemic heart diseases can be characterized by two main 
processes, namely the obstruction of the epicardial coronary arteries and coronary 
microvascular dysfunction [4]. With a varying proportion of contribution, these two 
mechanisms result in the disruption of the balance between the myocardial blood demand 
and supply [5]. This unbalance has a broad spectrum of clinical manifestations including 
silent ischemia, chronic stable angina [6], heart failure due to ischemic heart disease [7], 
sudden cardiac death [8] and acute coronary syndrome. This latter can be further 
subdivided into unstable angina and myocardial infarction with (STEMI) or without ST-
segment elevation (NSTEMI) on the electrocardiogram [9]. 
In-hospital lethality of acute coronary syndrome in most cases arises from those 
complications that compromise the pump function of the heart and eventually may result 
in cardiogenic shock [10]. The cause of cardiogenic shock in acute coronary syndrome is 
most often left ventricular failure and less frequently one of the mechanical consequences 
of myocardial necrosis like free wall, septal or papillary muscle rupture, which in turn 
lead to pericardial tamponade, left-right shunt or insufficiency of the mitral valve, 
respectively [11, 12]. Electrical complications including ventricular tachyarrhythmias 
with a lesser extent also contribute to the overall mortality of acute coronary syndrome, 
causing the death of 1.2-2.3% of the patients with myocardial infarction [13]. As a result 
of adequate revascularization therapy primarily by percutaneous coronary intervention or 
in some special cases by coronary artery bypass graft surgery the occurrence of the above 




steadily decreasing [14–17]. Despite these positive trends in the early mortality, in 
patients surviving acute myocardial infarction the occurrence of post-myocardial 
infarction heart failure showed a more modest reduction over the past decades [18, 19]. 
With a prevalence varying still between 14-36%, post-myocardial infarction heart failure 
remained a common consequence of acute coronary syndrome [20] and studies indicate 
that it is one of the main determinants of mortality after myocardial infarction [21, 22]. 
1.1.2 Successes and failures in developing cardioprotective approaches 
A robust correlation between infarct size and risk of post-myocardial infarction 
heart failure is supported both by the results of well-established animal studies [23] and 
clinical evidences [24]. However, due to the phenomenon of reperfusion injury infarct 
size increases even after a timely restoration of the coronary blood flow [25]. Thus, 
besides the minimization of the time between the onset of the first symptoms of 
myocardial infarction and revascularization (including the so-called door-to-balloon 
time) [26], alleviation of the reperfusion injury holds the opportunity to greatly improve 
survival after myocardial infarction. 
In 1986 significant reduction in the infarct size was observed in dogs treated with 
intermittent occlusions of the affected coronary artery before the actual ischemic insult 
[27]. The existence of this cardioprotective phenomenon, called preconditioning was later 
confirmed also in patients with pre-infarction angina [28]. Since then based on animal 
studies both remote ischemic conditioning and postconditioning were proposed as 
cardioprotective maneuvers, with a possibility to be applied within clinical setting [29, 
30]. However, in case of the remote ischemic conditioning large clinical studies refuted 
its effectiveness [31, 32]. 
Although enormous efforts were invested to identify key molecular pathways 
responsible for the cardioprotective effect of ischemic pre- and postconditioning and to 
identify drugs targeting the involved mediators, after successes with animal models, 
clinical studies were concluded with disappointing results uniformly [33]. Promising 
results with animal models in case of therapeutic hypothermia, the mitochondrial 
permeability transition pore inhibitor Cyclosporin-A or the delta-protein kinase C 
inhibitor delcasertib had failed to be translated into the clinical practice, to only name a 




Although the cause of the failure of these clinical studies are manifold, multiple 
recommendations were proposed to avoid them including two central ideas, namely the 
consideration of the modifying effect of comorbidities and comedications and the 
application of unbiased target identification [33, 37]. 
1.1.3 Role of comorbidities and comedications 
In the vast majority of the cases, acute myocardial infarction develops in patients 
also affected by at least one of the modifiable cardiovascular risk factors, such as 
hypertension, smoking, heart failure and metabolic disorders including diabetes mellitus, 
dyslipidemia, obesity and uremia [38–40]. The sustained presence of these comorbid risk 
factors leads to a remodeling process in both the vasculature and the myocardium, which 
could eventually impede the protective effect of the applied therapeutic interventions 
[41]. Several studies provided evidence for the interference between the above comorbid 
risk factors and the cardioprotective conditioning maneuvers [42, 43]. Furthermore, 
pharmaceutical agents administered to treat the concomitant risk factors and other 
comorbidities could also contribute to the failure of cardioprotection through the 
mechanism called hidden cardiotoxicity [43, 44]. The exact prevalence and combinations 
of the comorbid risk factors and comedications are not reflected by the experimental 
design of the preclinical studies of cardioprotection, which could serve as one of the 
possible explanations to the observed differences between the results of the preclinical 
and clinical studies [45]. Therefore, it is unavoidable to explore the effects of 
comorbidities and comedications on the cardiovascular system and to decipher molecular 
mechanisms responsible for these effects [33]. 
1.2 Unbiased, network theoretic target identification based on omics datasets 
In addition to neglecting the interaction of comorbidities and comedications with 
cardioprotection, biased, hypothesis-driven target identification could have also 
contributed to the failure of clinical translation of candidate cardioprotective agents [46]. 
Essential players in the pathomechanism could be overlooked because of the widespread 
practice of focusing on pathways that are already well-studied. To not miss such 
important mediators, an unbiased workflow was recommended to be applied, which 




evaluation of the resulting datasets, network theoretical target prediction and 
experimental validation of the selected targets [37]. 
1.2.1 Omics techniques 
High-throughput molecular biological methodologies make it possible to gain a 
global and detailed picture of the genotype (genomics), epigenetic modifications 
(epigenomics), gene expression at the RNA and protein levels (transcriptomics and 
proteomics) and the metabolite composition (metabolomics) of an organism. These 
methods together are called omics techniques and serve as fundamental pillars of network 
medicine [47, 48]. 
In case of rare, monogenic disorders rapid advancements in genomic methodologies 
made it possible to identify the pathogenic mutation which provides a good starting point 
to decipher the underlying molecular patomechanism [49]. An interesting example for 
these improvements is the discovery of the mutations in fibrillin-1 gene (FBN1) as a cause 
of Marfan syndrome, an autosomal dominant connective tissue disorder with serious 
aortic involvement [50]. It was later demonstrated that protein product of FBN1 in 
addition to being a structural protein of the extracellular matrix, can also sequester the 
isoforms of transforming growth factor beta (TGF-β) [51]. Consequently, the 
identification of pathogenic FBN1 mutations not just facilitated the elucidation of the 
TGF-β-mediated pathogenesis of Marfan syndrome, but also contributed to a more fine-
grained classification of overlapping phenotypes by the recognition of the disease causing 
role of genetic variants in genes related to the TGF-β signaling pathway [52]. This way 
patients having mutation in one of the genes encoding for TGF-β receptor 1 or 2 
(TGFBR1, TGFBR2), SMAD family member 3 (SMAD3) downstream mediator, TGF-β 
isoform 2 or 3 (TGFB2, TGFB3) are now diagnosed with Loeys-Dietz syndrome type 1-
5, respectively, instead of Marfan syndrome type II, which distinction also fosters a better 
risk stratification [53]. 
Whilst the ability to determine the nucleotide sequence of the entire human genome 
greatly increased the chance to unbiasedly explore the origin of monogenic disorders, in 
case of complex, multifactorial diseases it is much more cumbersome to find the link 




addition to static genomic data other omics techniques should be utilized to assess at least 
snapshots of the dynamical processes in the affected cells and tissues [46]. 
Although epigenomics measurements could provide us with truly valuable data on 
the functional state of the investigated cells, the unknown role of the possible histone 
modifications, technological problems with the detection of RNA-modifications and high 
cost are just a few examples of the great variety of difficulties that could limit the utility 
of epigenomics [55]. Similarly, in spite of significant improvements in the last decades, 
proteomics techniques still face with suboptimal reproducibility and coverage, and due to 
the lack of robust, standardized workflows the measurements are still recommended to be 
performed by highly specialized facilities after very careful preparation of the samples 
[56–58]. Among other challenges standardization of both the measurement techniques 
and the bioinformatics evaluation of the resulting raw data is also an issue in case of 
metabolomics [59, 60]. 
In contrast to the immature omics techniques discussed so far, well-established, 
highly standardized and relatively cheap technologies like DNA microarray, NanoString 
nCounter and RNA sequencing (RNA-seq) are available for the global profiling of the 
transcriptome [61]. DNA microarray technique, which is based on the hybridization of 
fluorescently labeled target sequences to the oligonucleotide probes attached to a solid 
surface, is a cost-effective and widely used methodology for differential expression 
analysis of various RNA species [62]. While DNA microarray technique requires reverse 
transcription and an optional amplification step, in case of NanoString nCounter target 
RNA sequences are hybridized directly to soluble fluorescently barcoded probe 
sequences, and quantified after immobilization to an imaging surface, which simplifies 
the workflow and avoids the bias introduced by amplification [63]. However, the 
coverage achievable by the latter two techniques is largely limited by the fact, that only 
those sequences could be measured, for which an oligonucleotide probe is available. It is 
especially an issue in case of NanoString nCounter as the maximum number of different 
barcodes is only 800 [64]. This limitation is totally absent in case of RNA-seq as after 
library preparation all RNA fragments can be further analyzed regardless of the 
nucleotide sequence. The library preparation step, which most commonly consists of the 
enrichment of the investigated sequences, reverse transcription, adaptor ligation and 




in a flow cell eventually producing tens of millions of sequencing reads [65]. After 
sequencing quality check, adaptor trimming, quality filtering, alignment of the raw RNA-
seq reads to the reference genome and feature counting are performed as steps of the 
recommended bioinformatics evaluation protocols [66, 67]. Proven and standardized 
statistical algorithms mostly in the form of packages for the R programming environment 
[68] are available for the normalization, differential expression analysis and 
dimensionality reduction of data assessed by both DNA microarray [69, 70] and RNA-
seq [71–73] measurements. 
Due to the lower number of microRNAs (about 2,300 [74]) compared to the protein 
coding transcripts (84,107 according to GENECODE reference annotation [75]) the 
starting point of an especially parsimonious approach to uncover key players in the 
pathomechanism of various diseases can be the assessment of the microRNA fingerprint 
of the experimental model relying on the above robust transcriptomics measurement 
workflows. As microRNAs are unavoidable players in the post-transcriptional regulation 
of gene expression, the most important mediators could be selected for further 
experimental validation by in silico analysis of microRNA expression profiles [76]. The 
utilization of these in silico approaches, however, requires the in-depth understanding of 
the network theoretic bases of the available bioinformatics toolset and more specifically 
a detailed knowledge of the complex biology of the post-transcriptional regulation of gene 
expression mediated by microRNAs. 
1.2.2 Basic concepts of network theory 
According to the classical definition big data can be characterized by three Vs: data 
of volume, velocity and variety that are difficult to be handled by usual means. Based on 
newer definitions veracity, that is the variable quality of the data could be also added as 
a fourth V [77]. Out of these four at least three (volume, variety, veracity) are common 
properties of datasets produced by omics technologies [78]. These challenges could be 
only solved by relying on advanced mathematical algorithms and computational 
approaches. Therefore, network theory by providing an objective, mathematical 
description of complex datasets is inevitable for the analysis of omics datasets [79]. 
The complexity of the interactions between entities like biomolecules can be 




interactions by edges. Nodes and edges of networks in turn can be described by 
mathematical terms using a pair of sets of vertices and links, respectively. Representation 
of networks by pair of sets is called a graph and provides an objective way to analyze 
networks with the rigorous toolset of discrete mathematics [80, 81]. In case of a network 
with n nodes an n × n matrix A, called the adjacency matrix can be used to describe the 
presence or absence of links between pairs of nodes. Element aij from the ith row and the 
jth column of matrix A is equal to 1 if an edge connects the ith and jth nodes, and 0, if 
there is no edge between these two nodes [82]. Instead of 0 or 1 a real value is assigned 
to each aij in case of weighted graphs, where the absolute value of this real number 
describes the strength of the interaction between the ith and jth nodes. To encode 
activating and inhibiting interactions positive and negative weights could be used, 
respectively. If the network is undirected the adjacency matrix is symmetric (i.e. equals 
to its transpose), while in case of directed networks there are differences between the 
value of the corresponding elements of the adjacency matrix above and below the main 
diagonal depending on the direction of the edges [80, 81]. 
The number of incoming edges of a node is called its degree, while the sum of the 
weight of the incoming edges is called the node strength [81]. Those regions of the 
network where the degree of the nodes mostly counts for the connections within this 
region rather than the remaining parts of the network are called modules or communities 
[83]. 
Most of the naturally occurring and artificial networks can be characterized by 
common fundamental properties like the observations that degree distribution of the 
nodes follows a power law (scale-freeness [84]) and instead of the expected linear relation 
the length of the shortest path between two nodes is proportional to the logarithm of the 
number of nodes in the network (small-worldness [85]). Similarly, in most of the cases 
networks exhibit a hierarchical structure [86] with a high degree of self-similarity [87]. 
1.2.3 Network visualization 
In addition to the objective mathematical description of networks with graphs, 
visualization of networks could facilitate the understanding of the functional relations 
between its constituents. However, in case of large, complex networks finding the best, 




the approaches available for network visualization utilize physical analogies treating 
nodes as balls repelling each other with springs between them to model edges with 
attraction forces [89, 90]. With different optimizations, like space partitioning, the time 
complexity of these algorithms can be significantly reduced [91], however, the resulting 
visualization is quite disappointing for larger real-world networks [88]. Another 
important shortcoming of these algorithms is the lack of an objective measure to quantify 
the quality of the layout. 
By representing nodes as two dimensional probability distributions, information 
theoretic approach of relative entropy optimization offers a solution for both above 
problems. Similarly to the adjacency matrix (A), which describes the topology of the 
network, an overlap matrix (B) can be populated by the pairwise overlaps calculated 
between the two dimensional probability distributions representing the nodes. This way 
the strength of the relation between two nodes, which is symbolized by the weight of the 
connecting edge in the adjacency matrix, could also be expressed in terms of the overlaps 
of the above probability distributions. As a result, the topology and the two dimensional 
visualization of the network can be represented by the adjacency matrix and the overlap 
matrix, respectively, and Kullback–Leibler divergence (relative entropy, D) can be 







where aij and bij are the elements in the ith row and the jth column of the A adjacency 
matrix and the B overlap matrix, respectively. This relative entropy value accounts for 
the difference between the information content of the original network topology and the 
two dimensional visualization. Therefore, minimization of the relative entropy function 
could result in achieving the optimal two dimensional layout of the network characterized 
by the lowest possible information loss [92]. Although this way the improvement of the 
visualization could be naturally and elegantly accompanied by a measure to quantify the 
layout quality, it remained an open question whether this algorithm can be implemented 
as a user-friendly application with reasonable time and space complexity, which could 




1.2.4 Network theoretical models of molecular biological processes 
Soon after the introduction of omics techniques it was noticed that advantages in 
the analysis of complex systems offered by objective mathematical evaluation and 
intuitive visualization of networks could be exploited for the investigation of various 
molecular biological systems [93]. Network topologies utilized for the evaluation of 
omics datasets can be classified into three main approaches based on the level of 
generality [79]. 
The first and most general approach is to reverse engineer the map of molecular 
biological interactions, and to construct and study so-called interactome networks, which 
are independent from the cell or tissue type and the phenotype [94]. Interactome networks 
can be further subdivided based on which biomolecules and interactions are represented 
by the nodes and the edges, respectively. While in gene regulatory networks genes are 
connected by edges symbolizing transcriptional regulation of gene expression [95, 96], 
protein-protein interaction networks are built of edges describing physical interactions 
between proteins [97]. MicroRNA-target interaction networks depict microRNAs and 
messenger RNA (mRNA) targets of microRNAs as nodes, and silencing interactions as 
edges [98]. Relying on these interactome networks either individual mediators or 
functional groups of mediators relevant in the pathogenesis of various diseases can be 
selected for experimental validation by network topological algorithms like the disease 
module approach [79]. Disease modules are communities in the interactome that are 
closely associated to various disease phenotypes [99]. 
As a second approach co-expression networks account for those algorithms that 
define the associations between biomolecules based on their relative abundance [100]. 
Assessing topological properties, like centrality measures and identifying modules in co-
expression networks could eventually reveal tissue-specific expression patterns that are 
responsible for the development of the studied phenotype [101]. 
In the third approach biological networks specific to tissue types and phenotypes or 
even for each individual samples are created and differences between them are 
investigated by the toolset of differential networking, which provides extra information 




1.3 MicroRNA-target interaction networks 
Beyond network theory development and utilization of bioinformatics tools for the 
analysis of microRNA transcriptomics datasets also necessitates a detailed knowledge of 
the highly complex nature of the post-transcriptional regulatory network realized by the 
interactions of various forms of coding and non-coding RNAs and RNA-binding proteins 
[104–106]. 
1.3.1 Role of microRNAs in the post-transcriptional regulation of gene expression 
The importance of post-transcriptional regulation could be best highlighted by the 
fact that while among physiological conditions it is a major determinant of differences 
between the proteomics profile of various tissues [107], alterations of it could contribute 
to the development of different kinds of diseases [108]. Besides RNA-binding proteins a 
central effector mechanism of the post-transcriptional regulatory network is RNA 
interference [109].  
RNA interference is an umbrella term for those small non-coding RNA-mediated 
processes that lead to the reduction of the expression of a target gene at either the mRNA 
or the protein level [110]. There are three classes of small non-coding RNAs that 
effectuate RNA interference, namely microRNAs (often abbreviated as miRNAs) with a 
mean length of approximately 22 nucleotides, the 20-25 nucleotides long small interfering 
RNAs (siRNAs) and the 23-29 nucleotides long so-called “Piwi-interacting” RNAs 
(piRNAs) [111, 112]. In contrast to piRNAs, which are created during the process called 
ping-pong cycle [113], endogenous or exogenous double-stranded RNAs and the hairpin 
structure of the pre-microRNAs are cleaved by the Dicer endoribonuclease to give rise to 
the mature form of siRNAs and microRNAs, respectively [110]. Small non-coding RNAs 
belonging to the above three classes associates to and guide the members of the Argonaute 
protein family to the appropriate target mRNAs based on sequence complementarity 
forming the RNA-induced silencing complex (RISC) [114]. While target mRNA cleavage 
requires perfect complementarity in case of siRNAs and most piRNAs, microRNAs (and 
some piRNAs) recognize their targets by the hybridization of the 6-7 nucleotides long 
seed region near the 5’ end of the microRNA to the 3’ untranslated region of the target 




by less powerful means like mRNA destabilization, mRNA degradation or translational 
inhibition, this permissive pairing rule makes the regulatory network of microRNAs 
highly intricate by allowing for one microRNA to bind to multiple mRNAs and one 
mRNA to be targeted by multiple microRNAs [116, 117]. This regulatory network is 
further complicated by dynamic phenomena like antagonism between microRNAs and 
sponging effects that is formulated within the competing endogenous RNA (ceRNA) 
hypothesis [104–106]. Therefore, it is obvious that the effect of alterations of microRNA 
expression profiles could only be predicted by taking into account the contribution of all 
microRNAs by network theoretic algorithms. 
1.3.2 MicroRNA target identification 
The primary prerequisite for inferring mRNA level transcriptomic changes from 
microRNA fingerprints is to identify the target genes of each microRNA showing 
expression changes between the studied phenotypes. Identification of the most relevant 
targets of microRNAs could happen based on either experimentally validated data or 
predictions assessed by various algorithms [106]. Although, records in experimentally 
validated, manually curated databases, like miRecords, miRTarBase or DIANA-TarBase 
are relatively reliable, these datasets only cover a tiny portion of the possible microRNA-
target interactions [98, 118, 119]. Therefore, relying solely on experimentally validated 
databases could result in overlooking many important interactions, that were not studied 
so far [120].  
Algorithms to predict microRNA targets, on the other hand, could provide full 
coverage of the possible interactions, they are still limited by a significant proportion of 
false positive findings [121]. One explanation for this poor specificity of prediction 
algorithms could be the fact that they focus on only few selected aspects of the greatly 
complex biology of the post-transcriptional regulatory system. The miRanda algorithm 
for example considers only sequence complementarity between the studied microRNA 
and its target [122], while the accompanying scoring algorithm, called mirSVR integrates 
the contribution of evolutionary conservation of the microRNA-target interaction, 
thermodynamic stability of microRNA-target complex and a few sequence related 
features into a support vector regression model [123]. Similarly, the MirTarget algorithm 




of the microRNA and the target by utilizing a support vector regression approach [124]. 
Conversely, PITA (Probability of Interaction by Target Accessibility) considers the 
binding site accessibility as a main determining factor of microRNA-target interactions 
[125]. Even though the context++ score of the TargetScan algorithm unites most of the 
above aspects in one comprehensive regression model, it still totally ignores the 
contribution of RNA-binding proteins [126]. This latter problem at least partly solved by 
the MREdictor algorithm, which searches for the well-conserved binding sites of Pumilio 
proteins, that could facilitate microRNA-mediated silencing by opening up the secondary 
structure of the target transcripts [127]. Nevertheless, one essential common shortcoming 
of all the currently available algorithms is that they are mostly based on such regression 
models and machine learning approaches, that are massively trained for the selected 
datasets [128]. This overfitting to the training set could likely explain how the authors of 
both TargetScan and MirTarget could have proved vice versa that their own algorithm is 
superior compared to the other [124, 126]. 
An additional problem is the relative lack of software tools that can consider the 
effect of multiple microRNAs on the same target. Currently there are only a few 
algorithms that is capable of analyzing microRNA-target interaction network as a whole 
[129, 130]. 
Here we propose that building and analyzing microRNA-target interaction 






We aimed to develop and validate two pieces of user-friendly software utilizing 
network theoretic algorithms to facilitate the identification of key pathways and 
functional modules in the interactome by the unbiased analysis of omics datasets. 
Firstly, our goal was to implement a network layout algorithm that is capable to 
visually highlight functional modules in the layout of real-world networks and to 
objectively quantify the quality of the resulting network visualization. 
The second purpose of this work was to develop a software that by evaluating 
transcriptomics profiles and by combining multiple publicly available microRNA-target 
interaction databases could select those genes that are most likely regulated by the set of 
differentially expressed microRNAs. We aimed to validate this latter software by 
analyzing the microRNA fingerprints of animal comorbidity models, to also contribute to 
the elucidation of the underlying pathomechanisms and to the identification of novel 





3.1 The EntOptLayout software 
To address the “hairball” problem of network visualization and to facilitate the 
quantification of the layout quality the relative entropy optimization algorithm proposed 
by Kovács et al. [92] was implemented as a user-friendly software called EntOptLayout 
and it was validated on several biological and synthetic networks. 
3.1.1 Software characteristics 
The EntOptLayout software was implemented in Java programming language as a 
plugin (http://apps.cytoscape.org/apps/entoptlayout) for the cross-platform compatible 
Cytoscape network analysis and visualization framework [131], therefore its graphical 
user interface is available for every major operating systems including GNU/Linux, 
macOS and Microsoft Windows. 
To improve calculation speed, the plugin divides the network into disconnected 
subgraphs and performs the optimization tasks on the resulting components separately. 
Adjacency matrices populated by edge weights of the network are stored using the 
compressed row storage (CRS) sparse matrix representation [132]. CRS significantly 
reduces the memory space complexity of the plugin compared to the conventional dense, 
two dimensional array representation while it still enables efficient reading of the matrix 
entries. Although CRS has a poor write performance, in case of adjacency matrices this 
limitation only affects the initialization phase, as no further modification of the adjacency 
matrix entries is needed during the layout calculation tasks. 
According to the relative entropy optimization algorithm [92] a probability 
distribution is assigned to each node and overlap matrices are calculated to describe the 
resulting layout. As elements of the overlap matrix are updated frequently and new values 
are read only a few times during the layout optimization, computation of the overlaps are 
performed on-the-fly, when they are needed without significant performance loss. 
To reduce relative entropy and consequently improve the quality of the network 
visualization besides position standard deviation and normalization (height) of the above 
mentioned probability distributions can be also optimized in separate calculation tasks. 




derivative of the functions describing the relation between relative entropy and the 
optimized parameter. 
Similarly, EntOptLayout plugin is capable to perform data ordering on the input 
network as a separate calculation task by optimizing node positions in one dimension. 
The ordered dataset can be exported as a conventional spreadsheet.  
When a calculation task is finished, raw and normalized relative entropy (i.e. 
normalized information loss) values are displayed in new columns added to the network 
table. Component-wise relative entropy values are also available in a separate Cytoscape 
table. With these numbers the user can easily follow the evolution of the network layout 
while it is converging to an optimal state. 
The EntOptLayout plugin provides three different user selectable main diagonal 
handling approaches for the adjacency and overlap matrices. It is optimal to ignore the 
main diagonal, when self-links are impossible or irrelevant in the network. If self-links 
are as relevant as the rest of the links in the network, double consideration of the main 
diagonal is recommended. The single option is kept only for compatibility and testing 
purposes. 
At the beginning of calculation tasks node positions can be either kept, initialized 
with random values based on a user defined random seed or with the visible coordinates. 
Similarly to other network layout plugins, column containing edge weights could be 
selected from a list box in EntOptLayout settings, however, visualization without 
considering edge weights is also possible. Although calculation tasks are stopped 
automatically when no further significant improvement can be achieved in the layout 
quality, a user adjustable time limit is also available to specify a maximal running time 
for larger networks. 
To highlight the structural characteristics of the network determined by mutual 
neighbors of the nodes, a special option to raise the adjacency matrix to the second power 
before starting calculations is also implemented in EntOptLayout. 
3.1.2 Validation of the EntOptLayout software 
The EntOptLayout algorithm was validated using both normal and diseased or 
perturbed versions of human and yeast interactomes and benchmark networks. Human 




[134] and a human immunodeficiency virus (HIV) related [135, 136] protein-protein 
interaction network, a biological pathway network (Reactome [137]) and a cancer 
signaling network [138]. One yeast protein-protein interaction network was analyzed both 
in its normal and heat shocked state [139] and also a Saccharomyces cerevisiae genetic 
interaction network was investigated [140].  
It was observed that using EntOptLayout after preprocessing of the layout by 
Cystoscape’s default Prefuse force-directed algorithm could result in better visualizations 
in terms of normalized information loss values compared to the case when EntOptLayout 
is applied alone (Figure 1). 
 
 
Figure 1 EntOptLayout visualizations of the Interactome3D protein-protein interaction 
network [133] (A, B) and a cancer signaling network [138] (C, D) with and without 
preprocessing by the Prefuse force-directed algorithm [141]. Functional protein 
complexes were identified by the ModuLand software [142] and were highlighted by 
various colors. Normalized information loss (D value) was indicated for each layout. 
On the Interactome3D protein-protein interaction network it was demonstrated that 
raising the adjacency matrix to the second power before the actual visualization could 
considerably reduce the normalized information loss both for layouts created by the so 
far best-performing Prefuse force-directed algorithm and those post-processed by 





Figure 2 Prefuse force-directed (A, B) and preprocessed EntOptLayout (C, D) 
visualizations of the Interactome3D protein-protein interaction network [133] with (B, 
D) and without (A, C) raising the adjacency matrix to the second power before layout 
optimization [141]. Functional protein complexes were identified by the ModuLand 
software and were highlighted by various colors. Normalized information loss (D value) 
was indicated for each layout. 
According to marked improvements in normalized information loss sequential 
position and width optimization of the studied biological networks using EntOptLayout 
consistently resulted in a better layout compared to the currently available network 
visualization algorithms. As shown in Figure 3 in case of the Interactome3D protein-
protein interaction network the visualization by EntOptLayout after preprocessing by the 
Prefuse force-directed algorithm and using the second power of the adjacency matrix 
option yielded a much lower relative entropy value (D = 0.077) compared to the layouts 
prepared by either the spring-embedded (D = 0.294) [89], the EClerize (D = 0.353) [143] 
or the Prefuse force-directed algorithm alone (D = 0.299) [131, 144]. 
When visualizing synthetic graphs generated with predefined number and overlap 
of the modules [145], it was clearly demonstrated that EntOptLayout with the second 
power of adjacency matrix option could separate modules much better than the best 
currently available algorithm (Figure 4). This improvement was also reflected by the 





Figure 3 Visualization of the Interactome3D protein-protein interaction network [133] 
by the Prefuse force-directed (A), the EntOptLayout (B), the spring-embedded (C) and 
the EClerize (D) algorithms [141]. Normalized information loss (D value) was indicated 
for each layout. 
 
Figure 4 Generated networks with mixing parameter of 0.1 (A, B) and 0.25 (C, D) of 
the predefined modules (blue, green and red) [145] visualized by the Prefuse force-
directed (A, C) and the EntOptLayout (B, D) algorithms [141]. Normalized information 




3.2 Software characteristics of the miRNAtarget software 
A software with a user-friendly, web-based graphical user interface 
(https://mirnatarget.com) called miRNAtarget was implemented in C++ programming 
language for the prediction of the most relevant common targets of differentially 
expressed microRNAs. MiRNAtarget constructs a microRNA-target interaction network 
by combining data from experimentally validated, manually curated (miRTarBase [98]) 
and predicted (microRNA.org [123], miRDB [124]) microRNA-target interaction 
databases. In this generated microRNA-target interaction network target hubs (i.e. target 
nodes with the greatest degree or node strength) are identified as mediators with the 
highest probability to be regulated by differentially expressed microRNAs [146, 147]. 
Target hubs predicted by the miRNAtarget software were experimentally validated 
in multiple projects [146–149] including two studies to investigate the direct myocardial 
effect of hypercholesterolemia and sensory neuropathy detailed in the next two chapters. 
3.3 Hypercholesterolemia-induced myocardial dysfunction 
Utilizing an unbiased study design [37] cardiac microRNA fingerprint of normo- 
and hypercholesterolemic rats were analyzed by the miRNAtarget software and predicted 
targets were experimentally validated to elucidate the molecular pathomechanism behind 
the primary myocardial dysfunction associated to hypercholesterolemia. 
 
Figure 5 Volcano plot showing the microRNAs upregulated (red) and downregulated 




3.3.1 Differentially expressed microRNAs 
After demonstrating the presence of hypercholesterolemia and myocardial 
dysfunction in Wistar rats (Rattus norvegicus) fed by cholesterol-enriched diet, cardiac 
microRNA expression profiles of treated and control rats were assessed by DNA 
microarray technique in a previous study [150]. Out of the 350 measured and 120 
detectable microRNAs 10 and 47 microRNAs showed downregulation and upregulation, 
respectively (Figure 5). 
3.3.2 Predicted microRNA targets 
The microRNA-target interaction network constructed by miRNAtarget from 
differentially expressed microRNAs and their predicted targets is shown in Figure 6A. 11 
targets were predicted to have a degree of at least 4 out of which 4 were selected for 
experimental validation based on review of the relevant literature (Figure 6B and C). 
 
Figure 6 EntOptLayout visualization of the microRNA-target interaction network of the 
down- (green) and upregulated (red) microRNAs and their predicted targets (blue) in the 
rat model of the hypercholesterolemia-induced myocardial dysfunction [146]. Target 
hubs are indicated by dark blue color (A). Four target hubs (Adrb2, Ppp3r1, Cask and 




The four candidate targets were beta-2 adrenergic receptor (Adrb2), calcineurin B type 1 
(Ppp3r1), calcium/calmodulin-dependent serine protein kinase (Cask) and 
serum/glucocorticoid regulated kinase 1 (Sgk1). 
3.3.3 Target validation 
Predicted downregulation of Adrb2 in the hypercholesterolemic hearts compared to 
the control group was successfully validated both on the mRNA and the protein levels, 
by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot 
measurements, respectively. Although, the expected downregulation of calcineurin B 
type 1 could not be observed on the mRNA (Ppp3r1) level, the protein product (CNB1) 
of this gene was significantly downregulated. In case of Cask we could not validate our 
predictions (Figure 7). Contrary to the data in the Human Protein Atlas on the cardiac 
expression of the human orthologue of Sgk1 [151], its expression on the mRNA level was 
not detected in our rat heart samples. 
 
Figure 7 qRT-PCR (A) and Western blot (B) validation results of the selected targets 
(Adrb2, Ppp3r1 and Cask) of microRNAs differentially expressed in the heart of rat 




Direct interaction between Adrb2 and two selected microRNAs, namely rno-miR-195 and 
rno-miR-322, was also demonstrated by microRNA-luciferase reporter assay (Figure 8). 
 
Figure 8 Results of the validation of direct interaction between rno-miR-195 and rno-
miR-322 and their predicted target Adrb2 by microRNA-luciferase reporter assay (A) 
and schematic structure diagram of the luciferase reporter vector (B) and  
beta-galactosidase reporter vector (C) used in this assay [146]. 
3.4 Sensory neuropathy-induced myocardial dysfunction 
Similarly to the investigation of hypercholesterolemia-induced myocardial 
dysfunction an unbiased, microRNA omics based study was conducted to unravel the role 
of microRNAs in the development of diastolic dysfunction related to sensory neuropathy, 
and miRNAtarget was further validated on the resulting dataset. 
3.4.1 Differentially expressed microRNAs 
Sensory neuropathy and consequent diastolic dysfunction was successfully induced 
by systemic capsaicin treatment in male Wistar rats as a model for the neurological and 
related cardiac consequences of diabetes mellitus [152]. By DNA microarray 
measurement performed on the rat hearts expression of 257 microRNAs was detected and 
in case of 8 microRNAs either significant differential expression or an absolute binary 





Table 1 List of differentially expressed microRNAs in the rat model of sensory 
neuropathy-induced diastolic dysfunction when compared to the control group [147]. 
Mean and standard deviation (SD) of binary logarithm of fold change (log2FC) are 
indicated. Expression changes with p < 0.05 calculated by unpaired Student’s t-test are 
marked with an asterisk (*). 
microRNA log2FC mean log2FC SD Regulation 
rno-miR-344b-1-3p −1.95 * 0.47 down 
rno-miR-466b-1-3p −1.10 * 0.49 down 
rno-miR-98-5p −1.07 1.26 down 
rno-let-7a-5p −1.03 1.21 down 
rno-miR-1-3p −0.88 1.19 down 
rno-miR-206-3p −0.86 1.23 down 
rno-miR-34b-3p 0.63 0.46 up 




Figure 9 EntOptLayout visualization of the predicted microRNA-target interaction 
network of differentially expressed microRNAs (red) in the rat model of sensory 
neuropathy-induced diastolic dysfunction when compared to the control group [147]. 
Predicted targets are represented by blue nodes, while target hubs with a degree of at 
least 3 are highlighted by dark blue color. Regions of the network containing the 




3.4.2 Predicted microRNA targets 
With the use of miRNAtarget software 15 microRNA targets with a degree of at 
least 3 was identified in the predicted microRNA-target interaction network (Figure 9). 
Out of these 15 predicted targets insulin-like growth factor 1 (Igf1), solute carrier family 
2 member 12 (Slc2a12), eukaryotic translation initiation factor 4E (Eif4e) and unc-51 like 
autophagy activating kinase 2 (Ulk2) were selected for experimental validation based on 
available literature data indicating their effect on myocardial function or their role in the 
pathogenesis of diabetes. 
3.4.3 Target validation 
In case of all four selected targets, namely Igf1, Slc2a12, Eif4e and Ulk2, the in 
silico predicted upregulation was observed even at the mRNA level by qRT-PCR as 
shown in Figure 10. 
 
Figure 10 Results of the qRT-PCR measurement of the mRNA level of four selected 
microRNA targets,  namely Igf1 (A), Slc2a12 (B), Eif4e (C) and Ulk2 (D), in the rat 
model of sensory neuropathy-induced diastolic dysfunction in comparison to the control 
group [147]. Comparisons were done by Student’s t-test and p-values under the 






In this study we successfully developed two software tools and demonstrated their 
usefulness in the unbiased, microRNA omics based approach for the investigation of the 
molecular pathomechanism of cardiovascular disorders and comorbidities, that could 
provide a way to avoid further failures in the clinical translation of drug candidates [37, 
76]. 
4.1 Improved visualization of biological networks 
Here we successfully implemented the relative entropy optimization algorithm [92] 
in the form of the user-friendly EntOptLayout network visualization plugin for the widely 
used Cytoscape network analysis framework demonstrating its advantages over currently 
available software tools. 
4.1.1 Objective measure for the quality of the network layouts 
A unique feature of the EntOptLayout plugin is the ability to measure the quality of 
the resulting layout in terms of the normalized information loss (D value). With this 
capability EntOptLayout makes it possible to objectively compare network visualizations 
and the performance of layout algorithms when applied on the same network. 
The minimization of the information loss as a central idea behind EntOptLayout 
also guarantees that the achieved layout visually reflects the information content of the 
network topology as precisely as it is reasonably possible [92]. 
4.1.2 Advances in the visual identification of functional modules in biological networks 
Utilizing relative information loss as a quality measure it was demonstrated that 
when applying alternating updates of the node positions and widths to avoid local minima 
of the relative entropy function, EntOptLayout outperforms the currently available 
network layout algorithms [89, 131, 143, 144] in visualizing protein-protein interaction, 
biological pathway and signaling networks. Furthermore, when compared to other 
algorithms visual discrimination of functional modules in the above biological networks 
and in generated random benchmark networks was easier in case of the visualizations 




second power was switched on. As identifying modules in interactomes or signaling 
networks bear a special importance for exploring genes related to certain diseases [99, 
153] and in drug discovery [154], the above capability to separate modules even by 
looking at the layout could be greatly beneficial for the analysis of biological networks.  
In addition, implementation details, like sparse matrix representation of the 
adjacency matrix [132] and on-the-fly calculation of the node overlaps instead of storing 
these values in dense matrices improved memory handling and thus made it possible to 
visualize large networks even on average hardware. 
4.1.3 Current limitations and future perspectives 
Even though our results suggest that EntOptLayout can reduce the relative 
information loss compared to other network visualization algorithms, this improvement 
is more pronounced if preprocessing is performed by force-directed methodologies before 
applying the relative entropy optimization. As predicted by Kovács et al. [92] the reason 
for this shortcoming is most likely that, while EntOptLayout could align nodes within 
local structures like modules with a so far unprecedented accuracy, macroscopic 
arrangement of these structures depends on the randomly generated initial position of the 
nodes. This way instead of the global optimum the resulting layouts represent one of the 
local minima determined by the macroscopic structure, which behavior could be 
prevented by applying a preprocessing step. 
In case of large networks, the recommended running time of EntOptLayout is 
10,000 seconds, which far exceeds the time requirement of other highly optimized, but 
less precise algorithms. Both above problems could be overcome by applying a 
hierarchical layout approach [92], which is currently being implemented by our team. 
Another possible problem with EntOptLayout is when using the option to raise the 
adjacency matrix to the second power, the resulting layouts are less visually pleasing by 
subjective measures. However, this is a tradeoff with which we have to face, if it is a 
requirement to be able to discriminate modules of the network even by looking at the 
layout. If a nice layout is preferred over a more meaningful one, it can be easily achieved 





4.2 Unbiased prediction of target hubs in microRNA-target networks 
For the unbiased, in silico prediction of the most relevant targets of differentially 
expressed microRNAs miRNAtarget software was implemented and successfully 
validated using microRNA expression profiles assessed from two cardiovascular 
comorbidity models. 
4.2.1 A validated software for accurate microRNA-target hub prediction 
Because of the poor coverage provided by experimentally validated microRNA-
target interaction databases [120] and the high proportion of false positive records in 
predicted databases [121], in this study we proposed to combine multiple sources of 
microRNA-target interaction data within a simple network theoretic model as 
implemented in the miRNAtarget software. Based on the successful experimental 
validation of most of the target expression changes predicted by the miRNAtarget 
software, the above approach to combine experimental [98] and predicted [123, 124] 
microRNA-target interaction data proved to be effective. This way both the elimination 
of many false positive microRNA-target interactions and the extension of coverage could 
be achieved. 
By identifying microRNA targets with high network theoretical centrality values, 
like node degree or node strength miRNAtarget also makes it possible to take into 
consideration the effect of all the differentially expressed microRNAs predicted to 
regulate the same target. This feature let us tackle the problem of the high complexity of 
microRNA-target interaction networks [116, 117] for which well-established tools were 
lacking so far [128]. 
With appropriate layout of microRNA-target interaction networks generated by 
miRNAtarget could be also used to visually identify the most relevant mediators and 
functional modules of the post-transcriptional regulatory mechanisms. For this purpose, 
all networks assessed by miRNAtarget was visualized by the EntOptLayout plugin 
achieving a visually pleasing layout, on which key mediators can be recognized easily. 
Furthermore, with a user-friendly web frontend miRNAtarget serves as a tool that 
can be used even by those researchers, who does not have previous bioinformatics 




approaches [37, 76] for the study of various diseases, hopefully even outside the domain 
of cardiovascular biology. 
4.2.2 Novel mediators identified as possible drug targets in cardiovascular 
comorbidities 
Based on our in silico predictions here we demonstrated the significant 
downregulation of beta-2 adrenergic receptor (Adrb2) on both the mRNA and protein 
level in the rat model of hypercholesterolemia-induced myocardial dysfunction. Predicted 
direct interaction between Adrb2 mRNA and two upregulated microRNAs was also 
verified in this study (rno-miR-195 and rno-miR-322) by luciferase reporter assay. In 
addition, downregulation of Adrb2 due to direct interaction with a third microRNA (rno-
miR-16) also predicted by miRNAtarget software was shown in an independent study 
[155]. Although, other mechanisms including transcriptional regulation or epigenetic 
changes could have also contributed to the downregulation of Adrb2, these findings 
support the presence of microRNA-mediated downregulation of Adrb2 in the 
hypercholesterolemic heart. As Adrb2 was previously shown to be an important 
determinant of cardiac function [156], the above alterations are likely related to the 
development of myocardial dysfunction in hypercholesterolemia. Similarly, in silico 
predicted downregulation of calcineurin B type 1 (Ppp3r1) was successfully validated at 
the protein level in the hypercholesterolemic rat hearts. Furthermore, another study 
provided experimental evidence for the direct regulation of Ppp3r1 by the members of 
the miR-30 family [157], which was independently predicted by our software as a reason 
for the expected expression change of Ppp3r1. Based on data available in the literature on 
the role of Ppp3r1 in heart failure and cardiac hypertrophy [158], downregulation of 
Ppp3r1 could have also contributed to the progression of myocardial dysfunction 
observed in our model. 
In case of the rat model of systemic neuropathy-induced myocardial dysfunction 
predicted upregulation of all four selected targets of the downregulated microRNAs were 
successfully validated at the mRNA level. Out of these validated targets upregulation of 
insulin-like growth factor 1 (Igf1) and its downstream signaling pathway mediated by 
mTOR (mechanistic target of rapamycin), which includes another one of our validated 




to be involved in various cardiac pathologies contributing to the development of cardiac 
hypertrophy and heart failure [159–161]. The third validated target in this study, unc-51 
like autophagy activating kinase 2 (Ulk2) is an activator of autophagy, which process 
participates in the development of diabetic cardiomyopathy [162, 163]. In addition, here 
we also validated the predicted upregulation of solute carrier family 2 member 12 
(Slc2a12), an insulin sensitive glucose transporter that according to literature data 
becomes more abundant on cardiomyocytes during diabetes [164, 165]. 
Following further functional validation the above mediators could serve as possible 
novel targets for therapeutic approaches for the treatment of myocardial dysfunction 
induced by comorbidities including hypercholesterolemia and diabetic neuropathy. 
4.2.3 Current limitations and future perspectives 
Although here it was proven, that miRNAtarget is capable to make accurate 
predictions even in case of complex microRNA-target interaction networks, in the rat 
model of hypercholesterolemia-induced myocardial dysfunction expected expression 
change of a target with especially high node degree, namely Cask, could not be validated 
experimentally. We suppose that this phenomenon is likely due to the presence of 
adenylate-uridylate-rich sequences in the Cask mRNA, that are capable to bind the ELAV 
like RNA binding protein 1 (Elavl1, also known as human antigen R), which in turn can 
inhibit the silencing effect of targeting microRNAs [166]. At the same time, in the Ppp3r1 
mRNA conserved binding sites of Pumilio RNA-binding proteins are located, which 
could explain the increased silencing effect of the interacting microRNAs in case of 
Ppp3r1, as synergism between microRNAs and Pumilio proteins is well established [167]. 
Taken together, these observations justify our ongoing efforts to include the effect of 
RNA-binding proteins in our microRNA-target interaction network model to obtain even 
more precise predictions. 
Moreover, prediction of intricate regulatory effects like those described within the 
ceRNA hypothesis [104–106], instead of the current barely topological approach requires 
a network dynamic analysis of microRNA-target interactions, which we are also working 
on at the time of writing. 
Targets predicted for the microRNAs differentially expressed in the rat model of 




by qRT-PCR, which obviously not cover the known repression effect of microRNAs on 
the translation [117]. It was, however, demonstrated previously that translational 
repression precedes target destabilization and its contribution to silencing is less 
substantial when compared to mRNA degradation due to target destabilization [168, 169]. 
Therefore, successful validation of predicted expression changes on the mRNA level by 
qRT-PCR is a strong indication for the existence of microRNA-target interactions, which 
was also acknowledged by one of the most popular experimentally validated microRNA-
target interaction databases [98]. 
Partly because of the above limitations, it is also important to note that in neither 
study can we exclude the possibility that the observed expression changes of the predicted 
targets could be at least in part a result of mechanisms independent from microRNA-
mediated silencing, like transcriptional or epigenetic regulation of gene expression [37]. 
Nevertheless, evidence for the direct interaction between Adrb2 and investigated 
microRNAs was demonstrated by luciferase reporter assay in case of the rat model of 
hypercholesterolemia-induced myocardial dysfunction, which further supports the 
validity of our in silico approach. 
Lastly, elucidation of the exact role of the newly identified targets in the 
pathomechanism requires further investigation in case of both models of comorbidity-





We developed and successfully validated two user-friendly software tools, namely 
EntOptLayout and miRNAtarget for the unbiased, network theoretic analysis of omics 
datasets to identify potential molecular drug targets. We conclude that the present thesis 
is based on the following novel findings: 
1. By utilizing the principle of relative entropy optimization and the novel approach 
of raising the adjacency matrix to the second power the EntOptLayout plugin 
performed markedly better in the spatial separation of functional modules of 
biological networks compared to the currently available best-performing software 
tools, this way facilitating the identification of key mediators even by visual 
inspection of the network layout.  
2. Normalized information loss values calculated by EntOptLayout for the objective 
quantification of the quality of the network arrangements, also demonstrated that 
visualizations produced by EntOptLayout are superior than the ones assessed by 
traditionally best-performing algorithms. 
3. The miRNAtarget software, which we made available also as a web based tool, 
for improved coverage and quality utilizes microRNA-target interaction data from 
multiple experimentally validated and predicted databases to construct and 
analyze a microRNA-target interaction network. MicroRNA-target hubs with the 
highest node degree, identified by miRNAtarget as the most relevant mediators, 
were successfully validated by multiple experimental approaches in two animal 
models of cardiovascular comorbidities, providing evidence for the utility of 
miRNAtarget. 
4. In addition to the validation of miRNAtarget, by the unbiased, omics based 
investigation of the above two comorbidity models we first identified and 
validated potential new drug targets for the treatment of myocardial dysfunction 
induced by hypercholesterolemia (Adrb2, Ppp3r1) and sensory neuropathy (Igf1, 






Despite the great epidemiologic burden of ischemic heart disease all attempts for 
the clinical translation of cardioprotective approaches was notoriously unsuccessful so 
far. Based on a growing body of evidence the reason for these failures is twofold. Firstly, 
the modifying effect of comorbidities are ignored during the preclinical studies of 
ischemic heart disease, and secondly novel targets in most cases were identified by 
utilizing biased, hypothesis-driven methodologies. In addition, the second problem is 
further aggravated by the lack of user-friendly software tools for the unbiased analysis of 
huge omics datasets belonging to the domain of big data. 
Therefore, our aim was to develop and validate two easy-to-use software tools 
utilizing network theoretic principles for the analysis of omics datasets especially 
focusing on microRNA expression profiles. In addition, we aimed to identify possible 
novel molecular targets by the above in silico techniques in the experimental model of 
myocardial dysfunction induced by two comorbidities, namely hypercholesterolemia and 
sensory neuropathy. 
Here, we successfully implemented and validated the EntOptLayout network 
visualization plugin for the Cystoscape framework with a capability to objectively 
quantify the quality of network layouts by the normalized information loss value. It was 
demonstrated that on biological networks EntOptLayout outperforms the currently 
available best network visualization algorithms in terms of both the normalized 
information loss values and the spatial separation of functional modules. For network 
theoretical prediction of the most relevant common targets of differentially expressed 
microRNAs miRNAtarget software was developed and its predictions were validated 
experimentally using the samples gathered from our comorbidity animal models. As a 
result, predicted expression change of two targets in hypercholesterolemia-induced 
myocardial dysfunction (Adrb2, Ppp3r1), and four targets in sensory neuropathy-induced 
diastolic dysfunction (Igf1, Slc2a12, Eif4e, Ulk2) was confirmed experimentally. 
In summary novel in silico methods implemented and validated in this study could 
facilitate the unbiased analysis of omics datasets hopefully even outside the domain of 
cardiovascular biology, and after further investigation validated targets could serve as 
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